Last reviewed · How we verify

NCT03411759: FACIDOCRO

Cytochrome P450's Pharmacogenomics in Chronic Pain Patients

Completed Last updated 29 March 2018
What this trial tests

trial in Analgesia in 100 participants. Completed in 23 March 2018.

Timeline
8 January 2018
Primary endpoint
23 March 2018
23 March 2018

Quick facts

Lead sponsorUniversity of Bologna
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date8 January 2018
Primary completion23 March 2018
Estimated completion23 March 2018
Sites1 location across Italy

Conditions studied

Sponsor

University of Bologna

Who can join

Adults 18 to 90, any sex, with Analgesia or CYP2D6 Polymorphism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The use of titrated drugs is at the base of a successful antalgic treatment in order to provide both an adequate relief and a satisfactory tolerability profile. These molecules, though, have a varying degree of efficacy in different subjects due to medical and genetic reasons. The latter are mainly represented by cytochrome (CYP) P450, in particular CYP2D6's polymorphisms are responsible for the diversified metabolism of analgesics used in chronic pain treatments. Four main types of enzymatic metabolism make up the population, each one defined by a different CYP2D6 allele: extensive metabolizers, ultra-rapid metabolizers, intermediate metabolizers and poor metabolizers. Moreover, regarding polytherapies, the analgesics' metabolism could be influenced by coadministration of other drugs, thus determining an inhibition or induction of the metabolic enzymes - known as phenocopying - and potentially also a change in the metabolic phenotype itself. The final outcome is the inconstancy of effectiveness and of the risk of developing side effects. The primary objective of this study is to define a genetic pattern for the gene CYP2D6 by assessing the incidence of poor or ultrarapid metabolizers in a population of chronic pain patients. This will also allow to observe phenocopying in the same population. Hence 100 patients diagnosed with chronic pain will be enrolled. The genetic pattern of the gene CYP2D6 of such patients will be examined by taking mouth samples. At the same time parametric tests for paired data to survey the correlations between phenotypical patterns and pharmacological therapies will be conducted.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. An Explorative Study of CYP2D6's Polymorphism in a Sample of Chronic Pain Patients.
    Fanelli A, Palazzo C, Balzani E, Iuvaro A, et al · · 2020 · cited 1× · PMID 31710684 · DOI 10.1093/pm/pnz265

Verify or expand the search:

Other recruiting trials for Analgesia

Currently open trials in the same condition.

Other University of Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03411759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing